aTyr Pharma to launch new Phase 3 study of efzofitimod in pulmonary sarcoidosis after FDA feedback

aTYR PHARMA INC

Cash, cash equivalents, and investments totaled $68.3M as of March 31, 2026 (unaudited).
FDA Type C meeting endorsed FVC as primary endpoint and KSQ-Lung as key secondary in new Phase 3.
New trial to enroll ~372 patients with restrictive lung disease (FVC ≤80% predicted) on stable corticosteroids.
Dosing changed to 5.0 mg/kg every 3 weeks (from every 4 weeks) with enhanced safety monitoring.
Company plans to submit IND for this Phase 3 study in June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.